Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 4Head & Neck 3Gynecologic 3Dermatologic 2Breast 2Other hematologic neoplasm 1CNS 1

Conditions

Melanoma 2

Interventions

pembrolizumab 69Nivolumab 58Ipilimumab 35Specimen Handling 32Magnetic Resonance Spectroscopy 25Cyclophosphamide 22Biopsy 18cemiplimab 14fludarabine 13relatlimab 11binimetinib 11Opdualag 11trametinib 10fludarabine phosphate 10Radiosurgery 10CTLA-4 Antigen 10avelumab 9lifileucel 8dabrafenib 8Radiotherapy 8atezolizumab 7aldesleukin 7Paclitaxel 7Blood Specimen Collection 7encorafenib 6X-Rays 6Standard of Care 6Interleukin-2 6Immunoglobulin G 6HhAntag691 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunotherapy × Dermatologic × 90 days × Clear all
NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡